A leading biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines in areas such as antiviral, oncology, and inflammatory diseases, with a strong portfolio in HIV, hepatitis, and COVID-19 therapies.
Notice Date
November 13, 2024
—
January 17, 2025
Permanent
Seattle
Washington
